Unmet Need Can Trump Anything At US FDA Panels, Even An Ill-Prepared Sponsor
Emmaus was unable to answer several questions about its product and was also missing several pieces of data, but FDA's Oncologic Drugs Advisory Committee didn't criticize the sponsor, and instead praised it for paying attention to the largely neglected sickle cell disease.
You may also be interested in...
With an eye on a patient population mainly covered by Medicare and Medicaid, Emmaus Life Sciences CEO Yutaka Niihara says the company wants to ensure its pharmaceutical grade L-glutamine product is accessible in the US.
Puma is in select company after winning a strong vote from US FDA’s Oncologic Drugs Advisory Committee in favor of approval of its new cancer drug neratinib.